BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 30396849)

  • 1. Role of
    Albano D; Zizioli V; Treglia G; Odicino F; Giubbini R; Bertagna F
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(1):10-16. PubMed ID: 30396849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnostic value of
    Kassem TW; Abdelaziz O; Emad-Eldin S
    Diagn Interv Imaging; 2017 Oct; 98(10):693-698. PubMed ID: 28734778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic performance of fluorine-18-fluorodeoxyglucose positron emission tomography imaging in uterine sarcomas: systematic review and meta-analysis of the literature.
    Sadeghi R; Zakavi SR; Hasanzadeh M; Treglia G; Giovanella L; Kadkhodayan S
    Int J Gynecol Cancer; 2013 Oct; 23(8):1349-56. PubMed ID: 23945203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffusion-weighted MRI and 18F-FDG-PET/CT imaging: competition or synergy as diagnostic methods to manage sarcoma of the uterus? A systematic review of the literature.
    Dubreuil J; Tordo J; Rubello D; Giammarile F; Skanjeti A
    Nucl Med Commun; 2017 Jan; 38(1):84-90. PubMed ID: 27898647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of 18F-FDG PET/CT in restaging and follow-up of patients with GIST.
    Albano D; Mattia B; Giubbini R; Bertagna F
    Abdom Radiol (NY); 2020 Mar; 45(3):644-651. PubMed ID: 31646354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-body positron emission tomography with 18F-fluorodeoxyglucose is an effective method to detect extra-pelvic recurrence in uterine sarcomas.
    Sung PL; Chen YJ; Liu RS; Shieh HJ; Wang PH; Yen MS; Wen KC; Shen SH; Lai CR; Yuan CC
    Eur J Gynaecol Oncol; 2008; 29(3):246-51. PubMed ID: 18592788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [
    Metser U; Kulanthaivelu R; Salawu A; Razak A; Mak V; Li X; Langer DL; MacCrostie P; Singnurkar A
    J Nucl Med; 2023 Sep; 64(9):1371-1377. PubMed ID: 37414444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of
    Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A
    Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of FDG PET-CT in detecting recurrence in patients with uterine sarcoma: comparison with conventional imaging.
    Sharma P; Kumar R; Singh H; Jeph S; Sharma JB; Jain SK; Sharma DN; Bal C; Malhotra A
    Nucl Med Commun; 2012 Feb; 33(2):185-90. PubMed ID: 22107993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of 18F-FDG PET/CT imaging in the staging, restaging, monitoring of response to therapy and surveillance of uterine leiomyosarcomas.
    Bélissant O; Champion L; Thevenet H; Weinmann P; Alberini JL
    Nucl Med Commun; 2018 Jul; 39(7):652-658. PubMed ID: 29683931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and Prognostic Value of
    Albano D; Familiari D; Fornito MC; Scalisi S; Laudicella R; Galia M; Grassedonio E; Ruggeri A; Ganduscio G; Messina M; Spada M; Midiri M; Alongi P
    Curr Radiopharm; 2020; 13(1):42-47. PubMed ID: 31595860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and prognostic value of
    Albano D; Zizioli V; Odicino F; Giubbini R; Bertagna F
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(2):87-93. PubMed ID: 30573388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of
    Dolci C; Ceppi L; Guerra L; Crivellaro C; Lamanna M; Adorni M; Elisei F; Bonazzi CM; Sina F; Fruscio R; Messa C
    Int J Gynecol Cancer; 2019 Oct; 29(8):1298-1303. PubMed ID: 31366569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A retrospective study comparing contrast-enhanced computed tomography with 18F-FDG-PET/CT in the early follow-up of patients with retroperitoneal sarcomas.
    Niccoli-Asabella A; Altini C; Notaristefano A; Merenda N; Altieri ML; Stabile-Ianora AA; Fanelli M; Rubini G
    Nucl Med Commun; 2013 Jan; 34(1):32-9. PubMed ID: 23111380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and prognostic
    Albano D; Bonacina M; Savelli G; Ferro P; Busnardo E; Gianolli L; Camoni L; Giubbini R; Bertagna F
    Jpn J Radiol; 2022 Jan; 40(1):66-74. PubMed ID: 34272721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advantages of
    Németh Z; Boér K; Borbély K
    Pathol Oncol Res; 2019 Jan; 25(1):131-136. PubMed ID: 28994004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic accuracy of integrated (18)F-FDG PET/CT for restaging patients with malignant germ cell tumours.
    Sharma P; Jain TK; Parida GK; Karunanithi S; Patel C; Sharma A; Thulkar S; Julka PK; Bal C; Kumar R
    Br J Radiol; 2014 Aug; 87(1040):20140263. PubMed ID: 24896199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.